Tirzepatide vs semaglutide: one compound, two mechanisms
Same drug class, different receptor profile. Here is the honest comparison, without the marketing gloss.
Semaglutide (Ozempic, Wegovy) was the first GLP-1 drug to break into mainstream weight-loss prescribing. Tirzepatide (Mounjaro, Zepbound) came next and appears to do more weight loss, more consistently, for most people. Why?
Different receptor profiles. Here is the honest version.
The short answer
Semaglutide is a GLP-1 receptor agonist. One receptor, one mechanism.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Two receptors, two mechanisms working at the same time.
In head-to-head SURPASS-2 (diabetes setting), tirzepatide produced more A1c reduction and more weight loss than semaglutide at comparable doses. The effect size is real and clinically meaningful.
In SURMOUNT-1 (weight-loss setting), tirzepatide produced ~20% body-weight loss at 15 mg. STEP-1 semaglutide at 2.4 mg (the Wegovy dose) produced ~15% body-weight loss. Different trials, different populations, but a consistent direction.
What GIP adds
GLP-1 (glucagon-like peptide-1) is released from the gut in response to food. It slows gastric emptying, increases satiety, and improves insulin secretion. Most GLP-1 drug effects come from these pathways.
GIP (glucose-dependent insulinotropic polypeptide) is released from the gut from different cells. Its effects on the body are more nuanced than GLP-1, and for decades researchers thought GIP was not a useful drug target. It turns out that simultaneously activating both GIP and GLP-1 produces outcomes that are more than additive.
The proposed mechanism (Peter Attia has covered this on The Drive): GIP activation in combination with GLP-1 may reduce the common GLP-1 side effects (nausea, GI upset) while amplifying the weight-loss signal. This is an active research area and not fully settled.
Side effect profile
Both drugs have similar side-effect profiles:
- GI symptoms: nausea, some reflux, occasional diarrhea or constipation, especially during titration
- Injection-site reactions: usually mild, occasional redness or induration
- Rare but serious: pancreatitis, gallbladder issues, thyroid C-cell tumors (rat data, uncertain human relevance), kidney impact in dehydrated patients
In trials, the two drugs produced similar discontinuation rates for tolerability. A subset of patients does not tolerate either drug well. There is not strong evidence that someone who fails on semaglutide will succeed on tirzepatide or vice versa, though it happens.
Practical differences
Dosing cadence: Both are weekly subcutaneous injections. Tirzepatide titration is 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over about 20 weeks. Semaglutide titration is 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over about 16 weeks.
Duration: Both drugs are long-acting. Once-weekly is the standard. Missing a dose by a day or two is not a crisis; missing a week starts to matter.
Reversibility: Both drugs have appetite-regulation effects that fade within a few weeks of stopping. Most users who stop either drug regain weight. This is not a criticism of the drugs; it is a statement about how appetite regulation works without ongoing input.
Cost: Mounjaro and Ozempic/Wegovy are similarly priced at the pharmacy level in most markets. Branded product through a Thai clinic is in the 8,000 to 15,000 THB per month range for either. Research-chem semaglutide is slightly cheaper and more available than research-chem tirzepatide in Asia, though tirzepatide availability has improved through 2026.
Which one should you start with
We do not tell you which drug to use. We route to clinics and vendors that cover both, and the clinical conversation is where the compound choice happens.
The rough heuristic (not medical advice, just operating logic): if you have tried semaglutide and plateaued, tirzepatide is worth a conversation. If you have never tried either, start with whichever your clinic stocks and prescribes routinely. The "better" drug is the one you can get reliably and afford sustainably.
What about retatrutide
Retatrutide is a triple agonist (GIP, GLP-1, glucagon) in late-stage trials in 2026. Early data looks promising. It is not yet widely available outside trial settings. We will write about it separately when it is.
If you want a clinic match
Take our quiz. Two minutes. We match you to a clinic that stocks the compound that fits your situation, with honest framing on the tradeoffs.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
What Attia and Huberman actually say about GLP-1 dosing
The credentialed clinicians have covered GLP-1 drugs for years. Here is what they actually say, not the clickbait version.
Cold chain for peptides: what 2-8°C actually means for potency
Heat degrades peptides. But not all peptides, not at all temperatures, not at all durations. The honest version of the cold-chain question.
SURMOUNT-1 in plain English: what the trial actually showed
The tirzepatide weight-loss trial that reset the market. Here is what it tested, what it found, and the parts the press skipped.